Role Of Ifosfamide Chemotherapy For Patients With Non-Metastatic Osteosarcoma: A Meta-Analysis With 1724 Patients
Jian Tu,Xianbiao Xie,Yongqian Wang,Lili Wen,Bo Wang,Xian Zhong,Xuqi Sun,Mengqi Wang,Jianqiu Kong,Gang Huang,Junqiang Yin,Jingnan Shen
2016-01-01
Abstract:Background: Chemotherapy improves the survival rate of patients with non-metastatic osteosarcoma from 20% to 70%. However, the role of ifosfamide (IFO) in combination with other agents is still controversial. We conducted this meta-analysis to assess the efficacy of IFO in patients with non-metastatic osteosarcoma. Methods: An electronic search of PubMed, The Cochrane Library and EMBASE was performed using the search terms osteosarcoma and ifosfamide for studies published prior to Sep 6, 2014. All randomized controlled trials and observational comparative studies were included to compare the regimens of IFO to those without IFO for patients with non-metastatic osteosarcoma. Results: Eight studies with a high quality of methodology were included in the analyses, involving 1724 patients. No significant differences were demonstrated in the 5-year event free survival (EFS) (OR = 0.98, 95% CI: 0.57-1.69, P = 0.94, random effects model), overall survival (OS) (OR = 0.74, 95% CI: 0.44-1.26, P = 0.27, random effects model) or histological response rate (OR = 1.09, 95% CI: 0.88-1.34, P = 0.44, random effects model) between regimens containing IFO and those without IFO. For patients without IFO receiving neo-adjuvant chemotherapy, good histological responders had a better 5-year EFS (OR = 0.50, 95% CI: 0.29-0.83, P = 0.008, fixed effects model) than poor responders even when salvage chemotherapy including IFO was performed. The regimens with IFO caused more myelo-suppressive events, such as leukopenia, thrombocytopenia, and febrile neutropenia, than those without IFO (P < 0.005, respectively). Conclusion: The non-metastatic osteosarcoma patients treated with IFO had a similar histological response rate and 5-year EFS and OS, but more myelo-suppressive events than the patients treated without IFO. Whether IFO can be recommended as a first line therapy for patients with non-metastatic osteosarcoma should be identified in further studies.